Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
137 hedge funds and large institutions have $354M invested in Aerie Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 53 reducing their positions, and 15 closing their positions.
1,011% more call options, than puts
Call options by funds: $100K | Put options by funds: $9K
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
1% more funds holding
Funds holding: 136 → 137 (+1)
19% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 53
19% less capital invested
Capital invested by funds: $437M → $354M (-$83.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.68M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.07M |
| 3 |
FAM
Fred Alger Management
New York
|
+$3.87M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.8M |
| 5 |
Walleye Capital
New York
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.15M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.75M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$6.21M |
| 4 |
Millennium Management
New York
|
-$4.15M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.74M |
AERI Hedge Fund Activity: Q2 2022 in Review
137 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2022, worth a combined $354M — down 19% from $437M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AERI positions and 15 closed out — a net gain of 5 holders — while 43 added to existing stakes and 53 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $8.68M. The largest seller was Morgan Stanley, cutting an estimated $8.15M.
- 137 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2022, up from 136 in Q1 2022.
- Funds reported $354M of Aerie Pharmaceuticals stock for Q2 2022, down 19% quarter-over-quarter.
- 20 funds opened new Aerie Pharmaceuticals positions in Q2 2022 and 15 closed out, a net change of +5 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2022 was Rubric Capital Management (New York), an estimated $8.68M added.
- The largest Aerie Pharmaceuticals seller in Q2 2022 was Morgan Stanley, an estimated $8.15M sold.
Based on aggregated 13F filings for Q2 2022.